Oxaliplatin for Gastric Cancer: 34 Real Stories

Stage IV Gastric Adenocarcinoma: Derek's Survivor Story

Patient Info: Derek Cooney, Male, 40s | Stage IV

Metastatic Site: peritoneum

At his first follow-up in June, scans showed no evidence of disease, and he later completed his pain-management fellowship.

MD AndersonRead more →

Gastric cancer surgery and adjuvant treatment followed by endocrine complications

Patient Info: Anonymized, Female, 40s

After cancer treatment, she was hospitalized with severe nutritional and endocrine complications and improved with hormone replacement and nutritional support.

PubMed CentralRead more →

Stage IV AFP-producing gastric cancer responds to chemotherapy and immunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative; pMMR; elevated AFP

Metastatic Site: liver|peritoneum

Imaging showed a sustained partial response, his AFP level returned to normal, and he continued maintenance serplulimab at the latest follow-up.

PubMed CentralRead more →

Complete response in Stage IV gastric cancer after chemotherapy, immunotherapy, and surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative; MSS; PD-L1 high

Metastatic Site: liver

He achieved a complete pathologic response and remained free of recurrence for 3 years and 3 months after surgery.

PubMed CentralRead more →

Recovery from severe liver injury during Stage III gastric cancer treatment

Patient Info: Anonymized, Male, 70+ | Stage III

At the last follow-up in August 2025, imaging showed no recurrence and his liver function remained normal.

PubMed CentralRead more →

ALK-Fusion Gastric Cancer Responds to Alectinib Before Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: DCTN1–ALK fusion; ATM p.E1724*; CDK6 amplification; HER2 negative; mismatch-repair proteins intact; later KRAS amplification

Metastatic Site: bone

Alectinib produced a partial response for about 11.5 months, but the cancer later progressed systemically and she died from uncontrollable gastrointestinal bleeding.

PubMed CentralRead more →

Metastatic gastric cancer with an ATM mutation responding to olaparib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: Pathogenic germline ATM mutation, HER2-negative, PD-L1 15%

Metastatic Site: peritoneum

He had a deep response lasting about 18 months, but imaging in December 2023 again showed peritoneal carcinomatosis.

PubMed CentralRead more →

Painful eye metastasis from Stage IV gastric cancer

Patient Info: Anonymized, male | Stage IV

Metastatic Site: bone, choroid of left eye

The eye surgery relieved his pain, but he died 2 months later.

PubMed CentralRead more →

Recurrent gastric cancer with bone metastases, venous thrombosis and chylothorax

Patient Info: Anonymized, male, 60s | Stage IV

Metastatic Site: bone

Biopsy-confirmed bone recurrence developed more than a year after surgery. He was too unwell for palliative chemotherapy and died a few months after transition to best supportive care.

PubMed CentralRead more →

Stage II Gastric Cancer: Sagan's Patient Story

Patient Info: Sagan | Stage II

Sagan reported completing cancer treatment and continued taking medicines for treatment-related symptoms while focusing on recovery.

Our Cancer StoriesRead more →

Stage IV gastric cancer with liver metastases cleared after chemotherapy, nivolumab and surgery

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1-positive, HER2-negative

Metastatic Site: liver

After treatment cleared the gastric and liver lesions, all anticancer therapy was stopped. He remained relapse-free with no evidence of disease for 32 months.

PubMed CentralRead more →

Stage IV gastric cancer with a TP53 blood finding traced to clonal hematopoiesis

Patient Info: Anonymized, male, 50s | Stage IV

Metastatic Site: distant lymph nodes

At age 57, 3 years 4 months after his Stage IV diagnosis, he remained alive after multiple lines of treatment; progression had occurred before his later-line regimens.

PubMed CentralRead more →

Metastatic hepatoid gastric adenocarcinoma achieving complete remission with sintilimab

Patient Info: Anonymized, male | Stage IV

Biomarkers: AFP markedly elevated

Metastatic Site: liver

By the fifth sintilimab cycle, gastroscopy showed no gastric tumor, CT showed no liver metastases and AFP had normalized; complete remission was confirmed and remained stable during subsequent treatment.

PubMed CentralRead more →

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed CentralRead more →

Kidney Injury During Nivolumab Treatment for Stage IV Gastric Cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Kidney function and proteinuria improved after nivolumab was stopped, but the gastric cancer progressed. Restarted nivolumab was ineffective, and treatment was changed to irinotecan.

PubMed CentralRead more →

Kidney Disease During Treatment for Metastatic Gastric Cancer

Patient Info: Anonymized, Male, 70+ | Stage Metastatic/Advanced

Metastatic Site: liver

His condition worsened with nephrotic syndrome, malnutrition, treatment side effects, and progressing metastases. He died 5 months after the kidney biopsy following a fatal cerebral bleed.

PubMed CentralRead more →

Stage IV gastric cancer treated with chemotherapy and hyperthermia in a patient with a vagus nerve stimulator

Patient Info: Anonymized, male, 50s | Stage IV

Metastatic Site: para-aortic lymph nodes, peritoneum

The gastric tumors and lymph-node disease initially shrank during treatment, but peritoneal dissemination developed. He died from progressive gastric cancer 8 months after treatment began.

PubMed CentralRead more →

Stage IV gastric cancer with low platelets managed so chemotherapy could continue

Patient Info: Anonymized, female, 60s | Stage IV

Chemotherapy was able to continue after partial splenic embolization, but the gastric cancer later progressed and she died from the disease.

PubMed CentralRead more →

Stage IV gastric cancer with low platelets managed so chemotherapy could continue — Case 2

Patient Info: Anonymized, female, 70+ | Stage IV

After partial splenic embolization, her platelet count recovered and thrombocytopenia did not recur. She was receiving second-line ramucirumab plus paclitaxel at the latest follow-up.

PubMed CentralRead more →

Stage IV gastric cancer with gastric outlet obstruction treated with a stent

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: para-aortic lymph nodes

The second stent allowed her to continue eating solid food. She died from progressive gastric cancer 3 months after the repeat stent procedure.

PubMed CentralRead more →

Locally invasive gastric cancer treated with chemotherapy followed by curative surgery

Patient Info: Anonymized, male, 70+ | Stage III

Biomarkers: HER2-negative

Six months after surgery, CT showed no recurrence.

PubMed CentralRead more →

Stage III gastric sarcomatoid carcinoma treated with surgery and chemotherapy

Patient Info: Anonymized, female, 50s | Stage III

She was alive and healthy at telephone follow-up 3 years after surgery.

PubMed CentralRead more →

Ramucirumab and paclitaxel for metastatic gastric cancer in a patient receiving hemodialysis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver, distant lymph nodes

After about 16 months of disease control on paclitaxel plus ramucirumab, multiple liver metastases and distant lymph nodes progressed. Third-line irinotecan was stopped after severe toxicity, and supportive care followed.

PubMed CentralRead more →

Dural metastasis causing seizures after treatment for signet-ring gastric cancer

Patient Info: Anonymized, female, Under 40 | Stage IV

Metastatic Site: dura mater

She died 16 days after hospital admission for neurologic symptoms, roughly 8 months after the original gastric-cancer diagnosis, following rapid deterioration from diffuse dural metastatic disease.

PubMed CentralRead more →